We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TB Alliance

News List

TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis prnasia
August 04, 2020
Pretomanid, a novel compound developed by the non-profit organization TB Alliance, has been granted a conditional marketing authorisation by the European Commission (EC) for treating highly drug-resistant forms of pulmonary tuberculosis (TB).1
TB Alliance, Mylan Announce Collaboration to Commercialize Pretomanid americanpharmaceuticalreview
April 19, 2019
Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).